Global Gene Delivery Technologies Market

Gene Delivery Technologies Market size was valued at USD 4.51 Bn. in 2023 and the total revenue is expected to grow at 12.2% through 2024 to 2030, reaching nearly USD 10.10 Bn. in the forecast period.

Gene Delivery Technologies Market Overview

Gene delivery technology involves three main elements such as plasmid-based gene expression system to control the gene function in the target cell, a gene to encode the particular therapeutic protein, and lastly gene delivery to control the gene expression plasmid to a location within the body. Moreover, a successful gene delivery system needs a foreign genetic molecule that remains stable in the host cell.To know about the Research Methodology :- Request Free Sample Report

Gene Delivery Technologies Market Dynamics:

Rising Nanotechnology and physical technology have developed the activation of physical gene delivery methods like megnetoporation, optoporation, sonoporation, and electroporation. This advancement in technology is gaining more attention due to improved functionality and nontoxicity nature. Further, these factors have boosted the application of products belonging to this category and created more opportunities for the market players in this field. In 2021, Thermo Fished Scientific Company invested USD 180 million for the construction of the new 290,000-ft2 facility in Plainville, MA. This investment helped to double the expansion of capacity for viral vector development and manufacturing services.

Further, the expansion increased the demand for the development and production of gene therapies and vaccines. This key factor boosted the research and development together with the manufacturing of gene delivery technologies to generated large outcomes in the market. In addition, growing gene delivering technologies smash the market and helped the budding market players to enter the field.

Moreover, the market players are applying business strategies like mergers and acquisitions to sustain in the market and generate more revenue. For example, Thermo Fisher Scientific (US) acquired Brammer Bio (Cambridge, US) for USD 1.7 Billion, and Catalent (US) acquired Paragon Bioservices (Baltimore, US) for USD 1.2 Billion in May 2019. Currently, there are only 34 marketed gene and cell therapies globally, as it is a new and high-value treatment with companies like Gilead Science Inc, Yescarta, Novartis AG’s being specifically active in terms of revenue generation in 2022. Moreover, the companies are in the hunt for support from CMOs to produce a viral vector. The largest CMOs are likely to create future demand and have significantly invested in ATMP manufacturing capacities.

Gene Delivery Technologies Market Segment Analysis:

The biological segment is anticipated to adhere to the growth of the Gene Delivery

Technologies Market. The biological segment is dominating with a 61.2% revenue share in 2023 in the gene delivery technologies market. The factors attributing to the market's growth are approvals for the viral vector-based gene therapy products and the rising viral vector research and development programs. These programs have authenticated the adoption of viral vectors for delivery mode. Moreover, the high cost of viral vector transmission and various clinical challenges with the viral system has decreased the market's growth.

The ex-Vivo segment is supplementing the growth of the Gene Delivery Technologies Market.

The ex-vivo segment is dominating the gene delivery technology market with a market share of 37% in the forecast period. The factors attributing to the growth of the market are high transduction efficiency before the implantation of cells in donor patients and low immunogenic response after the transplant.

Moreover, the Ex-vivo segment offers high transduction efficiency and this factor has further increased the application in the research and development sector. The in-vivo segment is second dominating in the method segment of the gene delivery technology market. As the method is the most preferred as the virus transfers genetic material from one bacterium to another. Further, various challenges like high target delivery and the consequences that occurred during the delivery may result in the fluctuating immune response and due to these challenges in vivo gene therapy is less preferred by researchers.

Gene Therapy segment is Trending in the End-User Segment of Gene Delivery Technologies Market.

The gene therapy segment is dominating in the application segment of the gene delivery technology market and accounted for 37.4% of the market share in 2023. The growth is attributed to the adoption of gene therapies for the treatment of diseases caused by a genetic mutation. Moreover, advancement in technology and acceptance of gene-based therapies together with clinical trials is the factor supplementing the market proliferation. Further, cancer gene therapy is positively influencing market growth.

Government authorization for the innovation of gene therapy products is likely to gain significant market share in the forecast period. The collaboration of market players like Guangping Gao and Dan Wang Partners with ASC Therapeutics to develop novel gene therapies for maple syrup urine disease is further boosting the market growth during the forecast period. Moreover, gene therapy for spinal muscular atrophy is likely to gain more attention in the forecast period. In addition, researchers are focusing on the development of viral-based vaccines for the SARS-CoV-2 infection and more than 15 research teams are likely to explore genetic instruction for developing nucleic acid vaccines.

Gene Delivery Technologies Market Regional Insights:

North America is leading in the Gene Delivery Technologies market due to the large no. of clinical trials carried out to evaluate the safety and efficacy of gene therapies to offer vital feasible treatment for diseases that occurred by genetic mutation or degeneration like cancer, HIV/AIDS, and genetic disorders in the US. Moreover, the companies are paying more attention to the supply and commercialization of gene therapies and technologies to the major organizations and headquarters in the US. These factors are fueling the growth of the market during the forecast period. In addition, new collaborations in research organizations and innovation projects like viral vector-based gene therapy trials are likely to boost the gene delivery technologies market.

Moreover, innovative technologies and instruments in the region to reduce labor work are further initiating market growth in favorable conditions. The Asia Pacific accounts for a significant market share and is likely to gain more attention due to increasing globalization and research and development activities by the biopharmaceutical industries. In addition, China has been marked as a leading country in the cell and gene therapy market due to advanced laboratories and clinical trials conducted in the region. As per the survey, more than 1000 clinical trials were conducted in 2019. This factor further supported the growth of the market.

The objective of the report is to present a comprehensive analysis of the Gene Delivery Technologies Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding the Market dynamics, structure by analyzing the market segments and project the Gene Delivery Technologies Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Gene Delivery Technologies Market make the report investor’s guide.

Gene Delivery Technologies Market Scope: Inquire before buying

Gene Delivery Technologies Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Gene Delivery Technologies Market, Key Players

1. Thermo Fisher Scientific, Inc.
2. QIAGEN
3. Horizon Discovery Group Co.
4. OriGene Technologies, Inc.
5. Oxford Biomedica
6. SignaGen Laboratories
7. Vectalys
8. Takara Bio Inc.
9. System Biosciences Llc
10.Promega Corporation
11.Hoffmann-La Roche AG
12.Sirion-Biotech GmbH
13.Catalent Inc
14.Bio-Rad Laboratories, Inc.

FAQs:

1. What is the Gene Delivery Technologies Market share in 2023?
Ans: Approximately, USD 4.51 Billion.

2. What is the Gene Delivery Technologies Market growth?
Ans: The Gene Delivery Technologies Market is anticipated to grow with a CAGR of 12.2% in the forecast period and is likely to reach USD 10.10 Billion by the end of 2030.

3. Which Method is expected to dominate the Gene Delivery Technologies Market during the forecast period?
Ans: The Ex-vivo segment is considered to dominate the market with a revenue share of 37 % due to the adoption of gene-based therapies and rising clinical trials initiatives for the same.

4. Which region is expected to dominate the Gene Delivery Technologies Market during the forecast period?
Ans: North America dominates the Gene Delivery Technologies market owing to the large no. of clinical trials conducted in the region to offer viable treatment for genetic diseases.

5. Who are the key players in the Gene Delivery Technologies Market?
Ans: Thermo Fisher Scientific, Promega Corporation, F. Hoffmann-La Roche AG, QIAGEN NV, Takara Bio Inc., Oxford Biomedica, Catalent, Inc., Bio-Rad Laboratories, and Agilent Technologies, Inc.